Key Stats for IQV Stock
- This-Week Performance: 7%
- 52-Week Range: $135 to $247
- Valuation Model Target Price: $228
- Implied Upside: 30.6%
Value your favorite stocks like IQVIA Holdings with 5 years of analysts’ forecasts using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
IQVIA stock rose about 7% this week, climbing to around $174 per share after closing at $174.27 on March 2. The advance followed management commentary at Citi’s 2026 Unplugged MedTech and Life Sciences Access Day alongside a wave of institutional stake adjustments that signaled renewed investor engagement.
Shares remain below their $247 52 week high, but sentiment improved meaningfully over the week.
The stock moved higher as fresh third quarter filings showed notable buying activity among several large holders, reinforcing that long term institutions continue to actively position around the name.
TD Asset Management increased its stake by 11.4% to 117,277 shares worth $22.28 million, Keystone Investors boosted its position by 55.1% to 146,228 shares valued at $27.78 million, Mitsubishi UFJ Asset Management raised holdings by 5.3% to 341,807 shares worth $64.92 million, and Dana Investment Advisors increased its stake by 18.4% to 160,057 shares valued at $30.4 million.
At the same time, Handelsbanken Fonder AB cut its position by 28.4%, American Century Companies reduced its stake by 24.3%, Primecap Management trimmed holdings by 13.7%, and Clark Estates Inc. NY lowered its exposure by 25.8%.
Institutional investors still own about 89.62% of IQVIA, underscoring strong sponsorship despite ongoing portfolio rebalancing.
This week at Citi’s 2026 Access Day, management highlighted strong fourth quarter momentum in Technology and Analytics Solutions, which grew close to 10% reported and about 7% in constant currency, with double digit growth in the real world business.
The company guided the new Commercial Solutions segment to 7% to 9% reported growth and R&DS to about 4%, with acquisitions expected to add roughly 150 basis points to enterprise revenue growth.
Management emphasized that AI remains a structural advantage, noting around 150 AI agents deployed across 30 use cases, and CFO Michael Fedock said, “this whole shift to AI is fantastic for us.”
With cancellations normalizing back toward typical $2 billion levels after peaking near $3 billion in 2024 and management describing pipeline and RFP flow as healthy, the rebound reflects improving confidence in 2026 execution rather than short term speculation.
See analysts’ growth forecasts and price targets for IQVIA Holdings (It’s free) >>>
Is IQV Undervalued?
Under valuation assumptions, the stock is modeled using:
- Revenue Growth (CAGR): 5.9%
- Operating Margins: 16.5%
- Exit P/E Multiple: 13.7x
Revenue is projected to rise from $16.31 billion in 2025 toward $17.24 billion in 2026, reflecting steady mid single digit growth rather than a sharp reacceleration.
The key driver is mix. Continued expansion in higher margin data analytics, real world evidence, and AI enabled commercial tools can support profitability even if clinical growth remains moderate.
The Commercial Solutions segment, guided to 7% to 9% growth, benefits from improving drug launch activity and greater outsourcing of end to end commercialization.
At the same time, R&DS growth of about 4% remains solid in the current environment, especially with cancellations reverting toward historical norms and emerging biotech funding showing signs of recovery.
Based on these inputs, the valuation framework implies a target price of $227.63, suggesting about 30.6% total upside from $174. That return profile assumes margin stability and consistent mid single digit revenue expansion.
At current levels, IQVIA appears modestly undervalued, with 2026 performance tied to commercial outsourcing momentum, AI monetization across its data platform, and continued normalization in clinical demand.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does IQV Stock Have From Here?
Investors can estimate IQVIA Holdings potential share price, or what any stock could be worth, in under a minute using TIKR’s New Valuation Model tool.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
See IQVIA Holdings true value, or any stock’s, in under 60 seconds (Free with TIKR) >>>
